摘要
系统性红斑狼疮(SLE)是一种严重的可累及多脏器的自身免疫性疾病,临床表现各异,儿童SLE与成人相似,但发病率及病死率均高于成年人,易发生重要脏器损伤,因此早期诊断及治疗十分重要。随着对SLE发病机制的深入探究、细胞和分子生物学的发展,促进了SLE药物治疗的进步。糖皮质激素仍然在SLE治疗中起主导作用,免疫抑制剂是治疗SLE的基石,生物制剂为SLE患者带来了福音,非特异性免疫疗法为难治性及重症SLE患者争取了治疗时间,治疗方案的选择取决于疾病的严重程度。了解儿童SLE的治疗进展,理论与实践相结合,对控制病情、改善预后有深远的意义。现就近年来儿童SLE的治疗进展作一综述。
Systemic lupus erythematosus(SLE)is a serious multisystem autoimmune disease with different clinical manifestations.Childhood-onset SLE(cSLE)is similar to adult-onset SLE,while its morbidity and mortality are higher than adults,and it is prone to damage important organs.Therefore,early diagnosis and treatment are very important.With the in-depth exploration of the pathogenesis and the development of cell and molecular biology,the progress of drug therapy for SLE has been promoted.Immunosuppression still remains the cornerstone of treatment,and glucocorticoids still plays a leading role.Biologics bring the gospel to SLE patients,and non-specific immunotherapy gains treatment time for refractory and severe SLE patients.Treatment options are led by the level of disease severity.It is of great significance to understand the treatment progress of cSLE and combine theory with practice together to control the disease activity and improve the prognosis.This article reviews recent advances regarding the update on the treatment of cSLE in recent years.
作者
曾月
吴玉斌
Zeng Yue;Wu Yubin(Department of Pediatric Nephrology and Rheumatology,Shengjing Hospital of China Medical University,Shenyang 110004,China)
出处
《中华实用儿科临床杂志》
CAS
CSCD
北大核心
2021年第10期797-800,共4页
Chinese Journal of Applied Clinical Pediatrics
关键词
系统性红斑狼疮
治疗
进展
儿童
Systemic lupus erythematosus
Treatment
Progress
Child
